Heat shock proteins as hallmarks of cancer: insights from molecular mechanisms to therapeutic strategies

WF Zuo, Q Pang, X Zhu, QQ Yang, Q Zhao… - Journal of Hematology & …, 2024 - Springer
Heat shock proteins are essential molecular chaperones that play crucial roles in stabilizing
protein structures, facilitating the repair or degradation of damaged proteins, and …

Ubiquitin: Not just a one‐way ticket to the proteasome, but a therapeutic dial to fine‐tune the molecular landscape of disease

AH Kim, PM Chiknas, REC Lee - Clinical and Translational …, 2024 - Wiley Online Library
Recently, there is a rise in studies that recognize the importance of targeting ubiquitin and
related molecular machinery in various therapeutic contexts. Here we briefly discuss the …

Proteostasis perturbation of N-Myc leveraging HSP70 mediated protein turnover improves treatment of neuroendocrine prostate cancer

P Xu, JC Yang, B Chen, S Ning, X Zhang… - Nature …, 2024 - nature.com
N-Myc is a key driver of neuroblastoma and neuroendocrine prostate cancer (NEPC). One
potential way to circumvent the challenge of undruggable N-Myc is to target the protein …

Plexin D1 emerges as a novel target in the development of neural lineage plasticity in treatment-resistant prostate cancer

B Chen, P Xu, JC Yang, C Nip, L Wang, Y Shen, S Ning… - Oncogene, 2024 - nature.com
Abstract Treatment-induced neuroendocrine prostate cancer (t-NEPC) often arises from
adenocarcinoma via lineage plasticity in response to androgen receptor signaling inhibitors …

Heat shock cognate 70 protein is a novel target of nobiletin and its colonic metabolites in inhibiting colon carcinogenesis

Z Gao, J Zheng, X Wu, S Savinov, C Zhao, H Xiao - Food & Function, 2024 - pubs.rsc.org
Nobiletin (NBT) is a unique flavonoid mainly found in citrus fruits and has been reported to
inhibit colon carcinogenesis in multiple rodent models. However, the direct molecular targets …

Novel frontiers in urogenital cancers: from molecular bases to preclinical models to tailor personalized treatments in ovarian and prostate cancer patients

G De Lazzari, A Opattova, S Arena - Journal of Experimental & Clinical …, 2024 - Springer
Over the last few decades, the incidence of urogenital cancers has exhibited diverse trends
influenced by screening programs and geographical variations. Among women, there has …

STUB1 suppresses paclitaxel resistance in ovarian cancer through mediating HOXB3 ubiquitination to inhibit PARK7 expression

L Zhao, HL Yang, Y Wang, S Yang, Q Jiang… - Communications …, 2024 - nature.com
Paclitaxel (PTX) is a first-line drug for ovarian cancer (OC) treatment. However, the
regulatory mechanism of STUB1 on ferroptosis and PTX resistance in OC remains unclear …

Identification of druggable targets from the interactome of the Androgen Receptor and Serum Response Factor pathways in prostate cancer

H Azam, C Veale, K Zitzmann, S Marcone… - PloS one, 2024 - journals.plos.org
Background The Androgen Receptor (AR) pathway is crucial in driving the progression of
prostate cancer (PCa) to an advanced state. Despite the introduction of second-generation …

The interconnective role of the UPS and autophagy in the quality control of cancer mitochondria

W Xu, L Dong, J Dai, L Zhong, X Ouyang, J Li… - Cellular and Molecular …, 2025 - Springer
Uncontrollable cancer cell growth is characterized by the maintenance of cellular
homeostasis through the continuous accumulation of misfolded proteins and damaged …

[HTML][HTML] Plexin D1 emerges as a novel target in the development of neural lineage plasticity in treatment-resistant prostate cancer

C Liu, B Chen, P Xu, J Yang, C Nip, L Wang… - Research …, 2024 - ncbi.nlm.nih.gov
Abstract Treatment-induced neuroendocrine prostate cancer (t-NEPC) often arises from
adenocarcinoma via lineage plasticity in response to androgen receptor signaling inhibitors …